Pharmafile Logo

KOL Strategy

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen approved by FDA for multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

What’s the difference?

What value does your strategic planning add?

- PMLiVE

Boehringer Ingelheim expands immuno-oncology pipeline with $1.3bn Nerio acquisition

The deal gives the company access to a preclinical immune checkpoint inhibitor programme

- PMLiVE

FDA approves Sun Pharma’s oral JAK inhibitor Leqselvi to treat severe alopecia areata

The autoimmune disease currently affects around 700,000 people in the US

- PMLiVE

LEO Pharma receives CHMP recommendation for Anzupgo in chronic hand eczema

About 70% of patients with severe cases of the skin condition report problems performing everyday activities

- PMLiVE

AstraZeneca’s Calquence combination shows promise in chronic lymphocytic leukaemia

Approximately 4,000 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

The rare form of pulmonary hypertension affects around 30,000 people in the EU

- PMLiVE

Start SMART

Collecting the right data in the right way for the right reasons

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links